Association of p53 codon 72 polymorphisms with expression status of hormone receptors like ER, PR, and HER-2 in invasive ductal breast carcinoma in Bangladeshi women
DOI:
https://doi.org/10.3329/bsmmuj.v18i3.80619Keywords:
invasive ductal breast carcinoma, p53 codon polymorphism, hormone receptors, PCR-RFLPAbstract
Background: There is a lack of data on prevalent genetic factors among female breast cancer patients from Bangladesh. p53, a suppressor gene, is crucial in breast cancer’s aetiology. This study aimed to investigate the association between p53 codon 72 polymorphisms and invasive ductal breast carcinoma (IDC) in Bangladeshi women.
Methods: This study included 203 formalin-fixed paraffin-embedded specimens of histologically confirmed IDC, with immunohistochemical analyses for ER, PR, and HER-2 status from November 2021 to October 2022. The specimens were collected from one laboratory in each of the Dhaka and Chattogram cities. p53 codon 72 genotypes were detected using PCR-RFLP.
Results: Most patients (77%) were aged 41–60 years. All cases were IDC, with grade II (79.3%) and stage II being most prevalent (82%). ER-positive tumours were observed in 65.5% of patients, while 69% tumours were PR-negative and HER-2-negative. The GC (Arg/Pro) genotype was predominant (58.6%), followed by CC and GG (20.7% each). Statistically significant associations were found between the GC genotype and size less than 5 cm (P<0.01), axillary lymph node metastasis (P<0.01), and PR-negative tumours (P=0.02). Patients with GC+GG genotypes had higher odds of axillary lymph node metastasis (age, tumour grade and tumour stage adjusted odds ratio 21.8; 95% confidence interval 7.0–67.9), PR-negative tumours (aOR 0.2; 95% CI 0.1–0.6) and HER-2 negative tumours (aOR 0.3; 95% CI 0.1–0.9).
Conclusion: Our study suggests that the Arginine allele at p53 codon 72, in either homozygous or heterozygous form, is associated with more aggressive IDC features in Bangladeshi women, including axillary lymph node metastasis and hormone receptor negative tumours.
Downloads
References
Wang W, Sun Y, Li J, Bai H, Ren C, Feng Y, Wang S. Global, regional, and national burden of breast cancer in young women from 1990 to 2021: findings from the global burden of disease study 2021. BMC Cancer. 2025 Jun 6;25(1):1015. doi: https://doi.org/10.1186/s12885-025-14416-1
Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol. 2001 Mar;2(3):133-140. doi: https://doi.org/10.1016/S1470-2045(00)00254-0
Béroud C, Soussi T. p53 gene mutation: software and database. Nucleic Acids Res. 1998 Jan 1;26(1):200-204. doi: https://doi.org/10.1093/nar/26.1.200
He XF, Su J, Zhang Y, Huang X, Liu Y, Ding DP, Wang W, Arparkorn K. Association between the p53 polymorphisms and breast cancer risk: meta-analysis based on case-control study. Breast Cancer Res Treat. 2011 Nov;130(2):517-529. doi: https://doi.org/10.1007/s10549-011-1583-2
Gomez-Lazaro M, Fernandez-Gomez FJ, Jordán J. p53: twenty five years understanding the mechanism of genome protection. J Physiol Biochem. 2004 Dec;60(4):287-307. doi: https://doi.org/10.1007/BF03167075
Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene. 2007 Apr 2;26(15):2157-2165. doi: https://doi.org/10.1038/sj.onc.1210302
Sprague BL, Trentham-Dietz A, Garcia-Closas M, Newcomb PA, Titus-Ernstoff L, Hampton JM, Chanock SJ, Haines JL, Egan KM. Genetic variation in TP53 and risk of breast cancer in a population-based case control study. Carcinogenesis. 2007 Aug;28(8):1680-1686. doi: https://doi.org/10.1093/carcin/bgm097
Khan Y, Khan NU, Ali I, Khan S, Khan AU, Iqbal A, Adams BD. Significant association of BRCA1 (rs1799950), BRCA2 (rs144848) and TP53 (rs1042522) polymorphism with breast cancer risk in Pashtun population of Khyber Pakhtunkhwa, Pakistan. Mol Biol Rep. 2023 Jul;50(7):6087–6096. doi: https://doi.org/10.1007/s11033-023-08463-9
Tommiska J, Eerola H, Heinonen M, Salonen L, Kaare M, Tallila J, Ristimäki A, von Smitten K, Aittomäki K, Heikkilä P, Blomqvist C, Nevanlinna H. Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res. 2005 Jul 15;11(14):5098-5103. doi: https://doi.org/10.1158/1078-0432.CCR-05-0173
Baynes C, Healey CS, Pooley KA, Scollen S, Luben RN, Thompson DJ, Pharoah PD, Easton DF, Ponder BA, Dunning AM; SEARCH breast cancer study. Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk. Breast Cancer Res. 2007;9(2):R27. doi: https://doi.org/10.1186/bcr1669
Khadang B, Fattahi MJ, Talei A, Dehaghani AS, Ghaderi A. Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. Cancer Genet Cytogenet. 2007 Feb;173(1):38-42. doi: https://doi.org/10.1016/j.cancergencyto.2006.09.010
Huang XE, Hamajima N, Katsuda N, Matsuo K, Hirose K, Mizutani M, Iwata H, Miura S, Xiang J, Tokudome S, Tajima K. Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer. 2003;10(4):307-311. doi: https://doi.org/10.1007/BF02967650
Själander Själander A, Birgander R, Kivelä A, Beckman G. p53 polymorphisms and haplotypes in different ethnic groups. Hum Hered. 1995 May-Jun;45(3):144-149. doi: https://doi.org/10.1159/000154275
Ohayon T, Gershoni-Baruch R, Papa MZ, Distelman Menachem T, Eisenberg Barzilai S, Friedman E. The R72P P53 mutation is associated with familial breast cancer in Jewish women. Br J Cancer. 2005 Mar 28;92(6):1144-1148. doi: https://doi.org/10.1038/sj.bjc.6602451
Zhang Z, Wang M, Wu D, Wang M, Tong N, Tian Y, Zhang Z. P53 codon 72 polymorphism contributes to breast cancer risk: a meta-analysis based on 39 case-control studies. Breast Cancer Res Treat. 2010 Apr;120(2):509-517. doi: https://doi.org/10.1007/s10549-009-0480-4
Buyru N, Tigli H, Dalay N. P53 codon 72 polymorphism in breast cancer. Oncol Rep. 2003 May-Jun;10(3):711-714. PMID: 12684648
Hu Z, Li X, Yuan R, Ring BZ, Su L. Three common TP53 polymorphisms in susceptibility to breast cancer, evidence from meta-analysis. Breast Cancer Res Treat. 2010 Apr;120(3):705-714. doi: https://doi.org/10.1007/s10549-009-0488-9
Ma Y, Yang J, Liu Z, Zhang P, Yang Z, Wang Y, Qin H. No significant association between the TP53 codon 72 polymorphism and breast cancer risk: a meta-analysis of 21 studies involving 24,063 subjects. Breast Cancer Res Treat. 2011 Jan;125(1):201-205. doi: https://doi.org/10.1007/s10549-010-0920-1
Pietsch EC, Humbey O, Murphy ME. Polymorphisms in the p53 pathway. Oncogene. 2006 Mar 13;25(11):1602-1611. doi: https://doi.org/10.1038/sj.onc.1209367
Chang-Claude J, Ambrosone CB, Lilla C, Kropp S, Helmbold I, von Fournier D, Haase W, Sautter-Bihl ML, Wenz F, Schmezer P, Popanda O. Genetic polymorphisms in DNA repair and damage response genes and late normal tissue complications of radiotherapy for breast cancer. Br J Cancer. 2009 May 19;100(10):1680-1686. doi: https://doi.org/10.1038/sj.bjc.6605036
Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007 Jun;28(6):622-629. doi: https://doi.org/10.1002/humu.20495
Thermo Fisher Scientific. GeneJET FFPE DNA Purification Kit User Guide. Publication no. MAN0012673 Rev B. Waltham (MA): Thermo. Available from: https://assets.fishersci.com/TFS-Assets/LSG/manuals/MAN0012673_GeneJET_FFPE_DNA_Purification__UG.pdf [Accessed on 28 July 2025]
Doosti A, Zamani M, Dehkordi PG, Taheri S, Banitalebi M, Mahmoudzadeh M. Association of the p53 codon 72 polymorphism with colorectal cancer in South West of Iran. Sci Res Essays. International Scholarly and Scientific Research & Innovation. 2011 Mar 1;5(2):3148-3152. doi: https://doi.org/10.5281/zenodo.1330139
Mahmood S, Sivoňová MK, Matáková T, Dobrota D, Wsólová L, Dzian A, Mištuna D. Association of EGF and p53 gene polymorphisms and colorectal cancer risk in the Slovak population. Springer Nature Link. 2014 July 8; 9:405–416. doi: https://doi.org/10.2478/s11536-013-0300-4
Murphy ME. Polymorphic variants in the p53 pathway. Cell Death Differ. 2006 Jun;13(6):916-20. doi: https://doi.org/10.1038/sj.cdd.4401907
Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009 Feb;9(2):95-107. doi: https://doi.org/10.1038/nrc2584
Kamińska M, Ciszewski T, Łopacka-Szatan K, Miotła P, Starosławska E. Breast cancer risk factors. Prz Menopauzalny. 2015 Sep;14(3):196-202. doi: https://doi.org/10.5114/pm.2015.54346
Acharya SC, Jha AK, Manandhar T. Clinical profile of patients presenting with breast cancer in Nepal. Kathmandu Univ Med J (KUMJ). 2012 Jul-Sep;10(39):3-7. doi: https://doi.org/10.3126/kumj.v10i3.8009
Pathak R, Jha A, Neupane PR, Chalise S, Basnyat AS. Histopathological evaluation of carcinoma of breast. Journal of Pathology of Nepal. 2016 Mar 17; 6(11): 922-927. doi: https://doi.org/10.3126/jpn.v6i11.15674
Costa KA, Guillo LA. TP53 codon 72 polymorphism in pigmentary phenotypes. J Biosci. 2012 Mar;37(1):33-39. doi: https://doi.org/10.1007/s12038-012-9183-9
Damin AP, Frazzon AP, Damin DC, Roehe A, Hermes V, Zettler C, Alexandre CO. Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk. Cancer Detect Prev. 2006;30(6):523-529. doi: https://doi.org/10.1016/j.cdp.2006.09.007
Alawadi S, Ghabreau L, Alsaleh M, Abdulaziz Z, Rafeek M, Akil N, Alkhalaf M. P53 gene polymorphisms and breast cancer risk in Arab women. Med Oncol. 2011 Sep;28(3):709-715. doi: https://doi.org/10.1007/s12032-010-9505-4
Liu C, Zhang H, Shuang C, Lu Y, Jin F, Xu H, Lu P. Alterations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implications. Med Oncol. 2010 Sep;27(3):747-752. doi: https://doi.org/10.1007/s12032-009-9279-8
Ahn SG, Yoon CI, Lee JH, Lee HS, Park SE, Cha YJ, Cha C, Bae SJ, Lee KA, Jeong J. Low PR in ER(+)/HER2(-) breast cancer: high rates of TP53 mutation and high SUV. Endocr Relat Cancer. 2019 Feb;26(2):177-185. doi: https://doi.org/10.1530/ERC-18-0281
Chen FM, Ou-Yang F, Yang SF, Tsai EM, Hou MF. P53 codon 72 polymorphism in Taiwanese breast cancer patients. Kaohsiung J Med Sci. 2013 May;29(5):259-264. doi: https://doi.org/10.1016/j.kjms.2012.09.004
Kara N, Karakus N, Ulusoy AN, Ozaslan C, Gungor B, Bagci H. P53 codon 72 and HER2 codon 655 polymorphisms in Turkish breast cancer patients. DNA Cell Biol. 2010 Jul;29(7):387-392. doi: https://doi.org/10.1089/dna.2009.0995
Noma C, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S. Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. Cancer Lett. 2004 Jul 16;210(2):197-203. doi: https://doi.org/10.1016/j.canlet.2004.03.031. Erratum in: Cancer Lett. 2005 Sep 28;227(2):237. PMID: 15183535
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Md. Zillur Rahman, Md. Jibran Alam, Amlan Bhattacharjee, Md. Azizur Rahman Riyaz, Fahmida Binta Wali, Inzamamul Ismail Shawon, Syeda Rumman Aktar Siddiqui, Laila Khaleda, Mohammad Al-Forkan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
